Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has a cash flow conversion efficiency ratio of -0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-21.56 Million ≈ $-3.15 Million USD) by net assets (CN¥1.03 Billion ≈ $151.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Cheng Du Sheng Nuo Biotec Co. Ltd. A fund operations to measure how many days the company can operate on defensive assets alone.
Cheng Du Sheng Nuo Biotec Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cheng Du Sheng Nuo Biotec Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cheng Du Sheng Nuo Biotec Co. Ltd. A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Fasten Co Ltd
SHE:000890
|
0.332x |
|
Shijihengtong Technology Co. Ltd. A
SHE:301428
|
N/A |
|
Fireweed Zinc Ltd
V:FWZ
|
-0.677x |
|
Pharmicell
KO:005690
|
0.080x |
|
Henan Huaying Agricultural Development Co Ltd
SHE:002321
|
0.036x |
|
Tekla Life Sciences Investors
NYSE:HQL
|
-0.002x |
|
Yantai Ishikawa Sealing Technology Co.Ltd.
SHE:301020
|
0.002x |
|
Bridgewater Bancshares Inc
NASDAQ:BWB
|
0.030x |
Annual Cash Flow Conversion Efficiency for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)
The table below shows the annual cash flow conversion efficiency of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see 688117 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥918.32 Million ≈ $134.38 Million |
CN¥25.27 Million ≈ $3.70 Million |
0.028x | -72.01% |
| 2023-12-31 | CN¥880.10 Million ≈ $128.79 Million |
CN¥86.53 Million ≈ $12.66 Million |
0.098x | -14.99% |
| 2022-12-31 | CN¥826.74 Million ≈ $120.98 Million |
CN¥95.62 Million ≈ $13.99 Million |
0.116x | +73.26% |
| 2021-12-31 | CN¥785.14 Million ≈ $114.89 Million |
CN¥52.41 Million ≈ $7.67 Million |
0.067x | -63.87% |
| 2020-12-31 | CN¥437.57 Million ≈ $64.03 Million |
CN¥80.84 Million ≈ $11.83 Million |
0.185x | +124.95% |
| 2019-12-31 | CN¥376.46 Million ≈ $55.09 Million |
CN¥30.92 Million ≈ $4.52 Million |
0.082x | -59.40% |
| 2018-12-31 | CN¥327.35 Million ≈ $47.90 Million |
CN¥66.23 Million ≈ $9.69 Million |
0.202x | -16.00% |
| 2017-12-31 | CN¥241.74 Million ≈ $35.37 Million |
CN¥58.22 Million ≈ $8.52 Million |
0.241x | -- |
About Cheng Du Sheng Nuo Biotec Co. Ltd. A
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more